CytoDyn (CYDY) Long-Term Debt Repayments (2012 - 2020)

CytoDyn's (CYDY) quarterly Long-Term Debt Repayments came in at $460000.0 in Q2 2020, up 255655.56% on a QoQ basis from -$180.0 in Q2 2015.

CytoDyn (CYDY) Long-Term Debt Repayments (2012 - 2020) Analysis & Trends

CytoDyn (CYDY) has 4 years of Long-Term Debt Repayments data on file, last reported at $460000.0 in Q2 2020.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $460000.0 in Q2 2020, while the trailing twelve-month figure through May 2021 was $459820.0 (down 35.22% YoY) and the FY2021 annual result came in at $950000.0, down 56.52% from the prior year.
Long-Term Debt Repayments rose to $460000.0 in Q2 2020, from -$180.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $460000.0 in Q2 2020 to a low of $460000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	17.05 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	CytoDyn	258.01 Mn	258.01 Mn	-	-

Download Data